2018-11-19 Comments Off on Mirati Presents Data From Ongoing Phase 2 Clinical Trial Of Mocetinostat In Combination With Durvalumab At The SITC 33rd Annual Meeting Mirati Presents Data From Ongoing Phase 2 Clinical Trial Of Mocetinostat In Combination With Durvalumab At The SITC 33rd Annual Meeting SAN DIEGO, Nov. 9, 2018 /PRNewswire/ — Mirati Therapeutics, Inc.